Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.69 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.69 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29463863 | 1.00 | DPP4 (0.69) | DPP4DPP8GRIA2GRIA4CTSL | |
| SCHEMBL3149850 | 0.85 | DPP4 (0.67) | DPP4DPP8ADORA2AADORA1LMNA | |
| SCHEMBL3139641 | 0.82 | DPP4 (0.62) | DPP4DPP8ADORA2AADORA1LMNA | |
| SCHEMBL3143750 | 0.81 | DPP4 (1.00) | DPP4DPP8 | |
| SCHEMBL308832 | 0.75 | DPP4 (0.58) | DPP4DPP8LMNAGAARAB9A | |
| SCHEMBL3145172 | 0.73 | DPP4 (0.61) | DPP4DPP8ADORA2AADORA1LMNA | |
| SCHEMBL3149763 | 0.72 | DPP4 (0.67) | DPP4DPP8LMNAHPGDKMT2A | |
| SCHEMBL3154320 | 0.72 | DPP4 (0.62) | DPP4DPP8ADORA2AADORA1LMNA | |
| SCHEMBL6012147 | 0.70 | DPP4 (0.43) | DPP4DPP8LMNA | |
| SCHEMBL308134 | 0.70 | DPP4 (0.43) | DPP4DPP8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3348547-B1 | BENZIMIDAZOLE DERIVATIVES AS NAV 1.7 (SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT (SCN9A)) INHIBITORS FOR TREATING PAIN, DYSURIA AND MULTIPLE SCLEROSIS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2020-07-22 | — | — | EP | claimed |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-09-10 | — | — | US | claimed |
| EP-3348547-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE OF SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2018-07-18 | — | — | EP | claimed |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2018-06-21 | — | — | US | claimed |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-08 | — | — | US | claimed |
| CN-110612289-B | Deuterated benzimidazole compound and medical application thereof | 住友制药株式会社 | 2023-06-30 | — | — | CN | disclosed |
| CN-107922350-B | Novel benzimidazole compounds and medicinal use thereof | 大日本住友制药株式会社 | 2022-04-19 | — | — | CN | disclosed |
| US-11066372-B2 | Deuterated benzimidazole compound and medical use thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| EP-3348547-B1 | BENZIMIDAZOLE DERIVATIVES AS NAV 1.7 (SODIUM CHANNEL, VOLTAGE-GATED, TYPE IX, ALPHA SUBUNIT (SCN9A)) INHIBITORS FOR TREATING PAIN, DYSURIA AND MULTIPLE SCLEROSIS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2020-07-22 | — | — | EP | disclosed |
| CN-110612289-A | Deuterated benzimidazole compounds and medical application thereof | 大日本住友制药株式会社 | 2019-12-24 | — | — | CN | disclosed |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3348547-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE OF SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2018-07-18 | — | — | EP | disclosed |
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | Sumitomo Pharma Co., Ltd. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1753730-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118555-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-15 | — | — | WO | disclosed |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107211-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | KCNA7, SCN1A, KCNA1 | DPP4 3330/4885DPP8 2829/4885GRIA2 1500/4885 |
| US-10407395-B2 | Benzimidazole compound and medical use thereof | SCN1B, SCN1A, KCNA7 | DPP4 3090/4885DPP8 2857/4885GRIA2 1292/4885 |
| US-20180170881-A1 | NOVEL BENZIMIDAZOLE COMPOUND AND MEDICAL USE THEREOF | KCNA7, SCN1A, KCNA1 | DPP4 3330/4885DPP8 2829/4885GRIA2 1500/4885 |
| US-20050272765-A1 | Dipeptidyl peptidase inhibitors | DPP3, DPP4, DPP7 | DPP4 2/4885DPP8 5/4885GRIA2 4554/4885 |
| US-11066372-B2 | Deuterated benzimidazole compound and medical use thereof | HCN4, HCN3, SCN8A | DPP4 1625/4885DPP8 1271/4885GRIA2 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.